Home Metabolism Hydroxylase inhibitor Nepicastat (SYN-117) HCl For research use only.

Nepicastat (SYN-117) HCl

Nepicastat (SYN-117) HCl is a potent and selective inhibitor of both bovine and human dopamine-β-hydroxylase with IC50 of 8.5 nM and 9 nM, with negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors. Phase 2.

Nepicastat (SYN-117) HCl Chemical Structure

Nepicastat (SYN-117) HCl Chemical Structure

CAS No. 170151-24-3

Purity & Quality Control

Nepicastat (SYN-117) HCl Related Products

Signaling Pathway

Hydroxylase Signaling Pathways

Hydroxylase Signaling Pathway

Biological Activity

Description Nepicastat (SYN-117) HCl is a potent and selective inhibitor of both bovine and human dopamine-β-hydroxylase with IC50 of 8.5 nM and 9 nM, with negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors. Phase 2.
Targets
Bovine dopamine-beta-hydroxylase [1] Human dopamine-beta-hydroxylase [1]
8.5 nM 9 nM
In vitro
In vitro In vitro, Nepicastat hydrochloride shows the selective and concentration-dependent inhibition effects on bovine and human dopamine-beta-hydroxylase activity with IC50 of 8.5 nM and 9.0 nM, respectively. While Nepicastat hydrochloride has negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors. [1]
In Vivo
In vivo In the artery, left ventricle and cerebral cortex of spontaneously hypertensive rats (SHRs), Nepicastat hydrochloride reduces noradrenaline content, and increases dopamine content and dopamine/noradrenaline ratio in a dose-dependent manner. In addition, Nepicastat hydrochloride also produces the similar effects on noradrenaline, dopamine and dopamine/noradrenaline ratio in tissues and plasma of beagle dogs. [1] In inactin-anesthetized SHRs, Nepicastat hydrochloride (3 mg/kg, i.v.) produces the antihypertensive effects and causes a significant decrease in renal vascular resistance (38%) and an increase in renal blood flow (22%). [2] In dogs with chronic heart failure, low-dose Nepicastat hydrochloride (0.5 mg/kg) prevents left ventricular (LV) dysfunction and remodeling, and combination therapy of Nepicastat hydrochloride and enalapril results in additional improvements in all morphological features. [3] In rat brain, Nepicastat hydrochloride at a dose of 50 mg/kg ( i.p.) leads to the reduction of norepinephrine (NE) and blocks cocaine-primed reinstatement of cocaine seeking. [4]
Animal Research Animal Models Spontaneously hypertensive rats (SHRs).
Dosages ≤100 mg/kg
Administration Administered via p.o.

Chemical Information & Solubility

Molecular Weight 331.81 Formula

C14H15F2N3S.HCl
CAS No. 170151-24-3 SDF Download Nepicastat (SYN-117) HCl SDF
Smiles C1CC2=C(CC1N3C(=CNC3=S)CN)C=C(C=C2F)F.Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 66 mg/mL ( (198.9 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Could you please suggest a vehicle for in vivo Nepicastat HCl injection?

Answer:
S2695 can be dissolved in 5% Tween 80+35% PEG 300+ddH2O at 10mg/ml clearly. When preparing the solution, we added solvents individually and in order, and the compound finally dissolved completely. Please prepare the solution each time before use.

Tags: buy Nepicastat|Nepicastat ic50|Nepicastat price|Nepicastat cost|Nepicastat solubility dmso|Nepicastat purchase|Nepicastat manufacturer|Nepicastat research buy|Nepicastat order|Nepicastat mouse|Nepicastat chemical structure|Nepicastat mw|Nepicastat molecular weight|Nepicastat datasheet|Nepicastat supplier|Nepicastat in vitro|Nepicastat cell line|Nepicastat concentration|Nepicastat nmr|Nepicastat in vivo|Nepicastat clinical trial|Nepicastat inhibitor|Nepicastat Metabolism inhibitor